Evaluation of immune-checkpoint molecules in dMMR/pMMR colorectal cancer by multiplex immunohistochemistry.

Sergei Sergeevich NaumovLiubov Alexandrovna TashirevaNadezhda Valerievna KrakhmalSergey Vladimirovich Vtorushin

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)

This study revealed a significant predominance of PD-L1, CTLA-4, LAG-3, and CD 3+ ,CD8+ lymphocytes in dMMR colorectal carcinomas. Further research on the immune landscape in different tumor compartments will likely have high prognostic value for CRC patients, as it might expand the criteria for prescribing immunotherapy.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
primary care
single cell
prognostic factors
peritoneal dialysis
emergency department
high throughput
high grade
adverse drug
patient reported